

Rosario Menendez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4115694/rosario-menendez-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

135
papers

4,631
citations

39
h-index

64
g-index

184
ext. papers

6,194
ext. citations

6.9
avg, IF

5.23
L-index

#	Paper	IF	Citations
135	One-year mortality after ICU admission due to COVID-19 infection.. <i>Intensive Care Medicine</i> , 2022 , 48, 366	14.5	2
134	Impact of time to intubation on mortality and pulmonary sequelae in critically ill patients with COVID-19: a prospective cohort study.. <i>Critical Care</i> , 2022 , 26, 18	10.8	4
133	Immune treatment in COVID-19.. <i>Revista Espanola De Quimioterapia</i> , 2022 , 35 Suppl 1, 59-63	1.6	0
132	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 41, 271	5.3	
131	Higher frequency of comorbidities in fully vaccinated patients admitted to ICU due to severe COVID-19: a prospective, multicenter, observational study. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
130	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1075-1085	11.6	3
129	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 25	51.1	31
128	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1087-1097	4.7	3
127	Differences in Nutritional Status and Inflammatory Biomarkers between Female and Male Patients with Bronchiectasis: A Large-Cohort Study. <i>Biomedicines</i> , 2021 , 9,	4.8	2
126	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. <i>Haematologica</i> , 2021 , 106, 1636-1646	6.6	15
125	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , 2021 , 159, 58-72	5.3	8
124	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 257-265	4.7	4
123	RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients. <i>Archivos De Bronconeumologia</i> , 2021 , 57, 28-35	0.7	17
122	Comparison of real-time and droplet digital PCR to detect and quantify SARS-CoV-2 RNA in plasma. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13501	4.6	8
121	Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. <i>Journal of Infection</i> , 2021 , 82, 261-269	18.9	14
120	Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. <i>Chest</i> , 2021 , 160, 187-198	5.3	64
119	Reduced Diffusion Capacity in COVID-19 Survivors. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1253-1255	4.7	18

118	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2021 , 1	5.8	3
117	Phenotypic Clustering in Non-Cystic Fibrosis Bronchiectasis Patients: The Role of Eosinophils in Disease Severity. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	4
116	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2021 ,	35.1	5
115	Long-term neuropsychiatric outcomes in COVID-19 survivors: A 1-year longitudinal study. <i>Journal of Internal Medicine</i> , 2021 ,	10.8	7
114	The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. <i>Critical Care</i> , 2021 , 25, 331	10.8	4
113	Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. <i>Translational Research</i> , 2021 , 236, 147-159	11	29
112	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). <i>Archivos De Bronconeumologia</i> , 2021 , 57, 21-27	0.7	11
111	ICU-Acquired Pneumonia Is Associated with Poor Health Post-COVID-19 Syndrome.. <i>Journal of Clinical Medicine</i> , 2021 , 11,	5.1	1
110	Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. <i>Critical Care</i> , 2020 , 24, 691	10.8	99
109	Reply to Dual antibiotic therapy for outpatient management of community-acquired pneumonia? <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
108	Reply to "Dual Antibiotic Therapy for Outpatient Management of Community-Acquired Pneumonia?". <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
107	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. <i>Chest</i> , 2020 , 158, 1896-1911	5.3	20
106	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020 , 39, 1513-1525	5.3	9
105	Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
104	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020 , 80, e23-e24	18.9	62
103	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. <i>Medical Sciences (Basel, Switzerland)</i> , 2020 , 8,	3.3	3
102	Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections 2020 , 212-228		
101	Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. <i>Archivos De Bronconeumologia</i> , 2020 , 56, 551-558	0.7	5

100	Neumonía intrahospitalaria. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumología</i> , 2020 , 56, 11-19	0.7	5
99	Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia. <i>Archivos De Bronconeumología</i> , 2020 , 56, 551-558	0.7	1
98	Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
97	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumología</i> , 2020 , 56, 1-10	0.7	11
96	Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2020 , 25, 543-551	3.6	12
95	Simultaneous Depression of Immunological Synapse and Endothelial Injury is Associated with Organ Dysfunction in Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	10
94	Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. <i>Chest</i> , 2019 , 156, 1080-1091	5.3	21
93	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
92	Soluble P-Selectin in Acute Exacerbations and Stable Bronchiectasis in Adults. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 1587-1591	4.7	2
91	Mucoid <i>Pseudomonas aeruginosa</i> alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2019 , 154, 40-46	4.6	4
90	Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. <i>Journal of Infection</i> , 2019 , 78, 423-431	18.9	28
89	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1482-1493	11.6	44
88	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	1
87	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019 , 60, 54-70	3.9	14
86	Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 370-378	10.2	23
85	Burden and risk factors for community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	56
84	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. <i>Journal of Infection</i> , 2018 , 77, 99-106	18.9	10
83	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. <i>Respiratory Medicine</i> , 2018 , 140, 115-121	4.6	6

82	The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry 2018 ,		3
81	Characteristics of patients with pulmonary non-tuberculous Mycobacterial infection in bronchiectasis: Data from the EMBARC registry 2018 ,		3
80	Primary ciliary dyskinesia in adults with bronchiectasis: Data from the Embarc registry 2018 ,		2
79	Bronchiectasis and Multidrug-resistant Microorganisms: The Ideal Niche?. <i>Archivos De Bronconeumologia</i> , 2018 , 54, 543-544	0.7	
78	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2017 , 151, 1311-1319	5.3	12
77	Research in community-acquired pneumonia: the next steps. <i>Intensive Care Medicine</i> , 2017 , 43, 1395-1397	4.5	5
76	New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1287-1297	10.2	103
75	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	149
74	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. <i>Respiratory Research</i> , 2017 , 18, 176	7.3	19
73	Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. <i>EBioMedicine</i> , 2017 , 24, 231-236	8.8	43
72	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017 , 17, 659	4	17
71	Solithromycin: the future of macrolide is now. <i>Annals of Research Hospitals</i> , 2017 , 1, 1-1	1.6	
70	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. <i>Vaccine</i> , 2017 , 35, 5264-5270	4.1	17
69	Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e35-e36	35.1	14
68	Influence of environmental conditions and pollution on the incidence of infections. <i>ERJ Open Research</i> , 2017 , 3,	3.5	2
67	Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry 2017 ,		2
66	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. <i>PLoS ONE</i> , 2017 , 12, e0175171	3.7	24
65	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2017 , 12, e0178022	3.7	9

64	Predicting In-Hospital Treatment Failure (≥ 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 82-92	2	17
63	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases</i> , 2016 , 16, 1364-1376	25.5	77
62	Age-related risk factors for bacterial aetiology in community-acquired pneumonia. <i>Respirology</i> , 2016 , 21, 1472-1479	3.6	16
61	From starting mechanical ventilation to ventilator-associated pneumonia, choosing the right moment to start antibiotic treatment. <i>Critical Care</i> , 2016 , 20, 169	10.8	13
60	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2016 , 48, 632-47	13.6	120
59	Challenges in managing <i>Pseudomonas aeruginosa</i> in non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2016 , 117, 179-89	4.6	51
58	Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. <i>Clinical Drug Investigation</i> , 2016 , 36, 41-53	3.2	20
57	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016 , 2,	3.5	84
56	Non-cystic fibrosis bronchiectasis: The long road to multidrug resistant bacteria. <i>Community Acquired Infection</i> , 2016 , 3, 110	0	2
55	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016 , 11, e0145929	3.7	44
54	Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome. <i>Journal of Infection</i> , 2016 , 73, 419-426	18.9	20
53	Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 677-86	27.4	306
52	Lung inflammatory pattern and antibiotic treatment in pneumonia. <i>Respiratory Research</i> , 2015 , 16, 15	7.3	24
51	Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1482-9	4.7	33
50	Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 153-60	4.7	84
49	C-Reactive Protein at Discharge, Diabetes Mellitus and ≥ Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 306-14	2	17
48	Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. <i>Journal of Infection</i> , 2015 , 71, 28-36	18.9	18
47	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , 2015 , 45, 1353-63	13.6	33

46	Severity and outcomes of community acquired pneumonia in asthmatic patients. <i>Respiratory Medicine</i> , 2014 , 108, 1713-22	4.6	10
45	Inflammatory response in mixed viral-bacterial community-acquired pneumonia. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 123	3.5	23
44	Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. <i>Respiratory Care</i> , 2014 , 59, 1550-9	2.1	8
43	Impact of microbial ecology on accuracy of surveillance cultures to predict multidrug resistant microorganisms causing ventilator-associated pneumonia. <i>Journal of Infection</i> , 2014 , 69, 333-40	18.9	7
42	Tobacco smoking increases the risk for death from pneumococcal pneumonia. <i>Chest</i> , 2014 , 146, 1029-1037	3.7	53
41	Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. <i>Respirology</i> , 2014 , 19, 929-35	3.6	14
40	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. <i>Respiratory Research</i> , 2014 , 15, 75	7.3	16
39	A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. <i>Respiratory Care</i> , 2014 , 59, 1078-85	2.1	36
38	Importance of <i>Aspergillus</i> spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. <i>Respiratory Research</i> , 2014 , 15, 17	7.3	35
37	Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 1241-8	10.2	40
36	Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. <i>Respirology</i> , 2013 , 18, 263-71	3.6	24
35	Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 143, 767-775	3.5	32
34	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. <i>Thorax</i> , 2013 , 68, 1007-14	7.3	66
33	Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. <i>Chest</i> , 2013 , 144, 1134-1142	5.3	71
32	Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. <i>Chest</i> , 2013 , 143, 1009-1017	5.3	42
31	Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 144, 999-1007	5.3	122
30	Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. <i>Chest</i> , 2012 , 141, 1537-1545	5.3	75
29	Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. <i>Critical Care</i> , 2012 , 16, R93	10.8	133

28	Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. <i>Journal of Infection</i> , 2012 , 65, 223-30	18.9	59
27	Biomarkers and community-acquired pneumonia: tailoring management with biological data. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 266-71	3.9	28
26	Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. <i>European Respiratory Journal</i> , 2012 , 39, 1144-55	13.6	80
25	Compliance with guidelines-recommended processes in pneumonia: impact of health status and initial signs. <i>PLoS ONE</i> , 2012 , 7, e37570	3.7	7
24	The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. <i>Clinics in Chest Medicine</i> , 2011 , 32, 491-505	5.3	10
23	Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in patients with acute respiratory distress syndrome and abdominal diseases: a preliminary observational study. <i>Critical Care</i> , 2011 , 15, R50	10.8	13
22	Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. <i>Critical Care Medicine</i> , 2011 , 39, 2211-7	1.4	78
21	Biomarkers and Pneumonia: Should We All be Using Them?. <i>Current Respiratory Medicine Reviews</i> , 2011 , 7, 262-267	0.3	
20	Community-Acquired Pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). <i>Archivos De Bronconeumologia</i> , 2010 , 46, 543-558	0.7	21
19	Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. <i>Journal of Infection</i> , 2010 , 60, 106-13	18.9	24
18	Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. <i>Chest</i> , 2009 , 135, 1572-1579	5.3	85
17	Meeting the old man's friend. <i>Thorax</i> , 2009 , 64, 1016-7	7.3	1
16	Impact of guidelines on outcome: the evidence. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009 , 30, 172-8	3.9	25
15	Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. <i>Archives of Internal Medicine</i> , 2009 , 169, 1515-24		78
14	A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. <i>Clinical Infectious Diseases</i> , 2009 , 49, 409-16	11.6	70
13	Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. <i>Clinical Infectious Diseases</i> , 2009 , 48, 377-85	11.6	116
12	Systemic inflammatory response and increased risk for ventilator-associated pneumonia: a preliminary study. <i>Critical Care Medicine</i> , 2009 , 37, 1691-5	1.4	23
11	Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. <i>Current Opinion in Pulmonary Medicine</i> , 2008 , 14, 219-27	3	98

10	A worldwide perspective of atypical pathogens in community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 1086-93	10.2	171
9	Treatment failure in community-acquired pneumonia. <i>Chest</i> , 2007 , 132, 1348-55	5.3	56
8	Atypical Coverage for Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 1289-1290	10.2	
7	Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 757-62	10.2	128
6	Reply to De Maria et al.. <i>Clinical Infectious Diseases</i> , 2005 , 40, 1375-1376	11.6	
5	Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1783-90	11.6	106
4	Influence of deviation from guidelines on the outcome of community-acquired pneumonia. <i>Chest</i> , 2002 , 122, 612-7	5.3	81
3	Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 159, 1868-73	10.2	95
2	Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. <i>Respiration</i> , 1998 , 65, 108-13	3.7	107
1	Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. <i>Emerging Microbes and Infections</i> , 1-67	18.9	0